Human Papillomavirus Infections - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 106 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Human Papillomavirus Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Human Papillomavirus Infections - Pipeline Review, H2 2014', provides an overview of the Human Papillomavirus Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Human Papillomavirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Human Papillomavirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Human Papillomavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Human Papillomavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Human Papillomavirus Infections Overview 10
Therapeutics Development 11
Pipeline Products for Human Papillomavirus Infections - Overview 11
Pipeline Products for Human Papillomavirus Infections - Comparative Analysis 12
Human Papillomavirus Infections - Therapeutics under Development by Companies 13
Human Papillomavirus Infections - Therapeutics under Investigation by Universities/Institutes 16
Human Papillomavirus Infections - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Human Papillomavirus Infections - Products under Development by Companies 21
Human Papillomavirus Infections - Products under Investigation by Universities/Institutes 22
Human Papillomavirus Infections - Companies Involved in Therapeutics Development 23
Merck & Co., Inc. 23
Takeda Pharmaceutical Company Limited 24
MediGene AG 25
Chong Kun Dang Pharmaceutical Corp. 26
Crucell N.V. 27
Starpharma Holdings Limited 28
Bharat Biotech International Limited 29
FluGen, Inc. 30
Genticel 31
Vaxart, Inc. 32
Selecta Biosciences, Inc. 33
Spider Biotech 34
Indian Immunologicals Limited 35
Beijing Minhai Biotechnology Co., Ltd 36
Shanghai Zerun Biotechnology Co., Ltd. 37
Chongqing Zhifei Biological Products Co., Ltd. 38
Immunservice GmbH 39
Redbiotec AG 40
Agilvax, Inc. 41
Nielsen Biosciences, Inc. 42
Human Papillomavirus Infections - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
V-503 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ProCervix - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
astodrimer - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AV2-DM - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Candida Albicans Antigen - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
human papilloma virus vaccine [types 16 and 18] - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CKD-12201 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Recombinant Vector Vaccine for Human Papillomavirus Infections - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
RBT-201 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
human papillomavirus vaccine [serotypes 16, 31] - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
human papillomavirus vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
AX-03 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
human papillomavirus vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
human papillomavirus vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
human papillomavirus vaccine (tetravalent) - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
human papilloma virus vaccine [types 16 and 18] - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecule Inhibiting Kinases for Viral Infections - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Human Papillomavirus Vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
human papillomavirus vaccine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ISANIL-01 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
SB-206 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Human Papillomavirus Vaccine Program - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PL-202 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
human papilloma virus vaccine - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
HPV vaccine second generation - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Human Papilloma Virus Vaccine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules to Target Heparan Sulfate for Bacterial and Viral Infections - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
SB105-A10 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Vaccine for Human Papillomavirus Infections - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
human papillomavirus vaccine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules for HPV Infections - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
human papillomavirus vaccine - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
HTI-1968 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Monoclonal Antibody for HPV - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Human Papillomavirus Infections - Recent Pipeline Updates 90
Human Papillomavirus Infections - Dormant Projects 95
Human Papillomavirus Infections - Discontinued Products 96
Human Papillomavirus Infections - Product Development Milestones 97
Featured News & Press Releases 97
Jul 10, 2014: Genticel's Phase II study with Procervix passes the halfway mark for patient recruitment 97
Jun 10, 2014: Inovio Pharmaceuticals Initiates Immune Therapy Trial for Head & Neck Cancer Caused by HPV 97
Apr 07, 2014: Gardasil approved in the European Union for a 2-dose schedule in children aged from 9 to 13 years 98
Feb 20, 2014: FDA Accepts for Review Merck's Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine 99
Nov 04, 2013: Merck's Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study 99
Oct 24, 2013: Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices 101
May 09, 2013: GSK Announces New Commitment With GAVI Alliance To Supply Cervical Cancer Vaccine 102
May 09, 2013: Merck Receives Significant Portion Of UNICEF Human Papillomavirus Vaccine Tender 102
Apr 30, 2013: Immunogenicity Of Two Doses Of Merck's HPV Vaccine May Be As Effective As Three, Study Finds 103
Dec 19, 2012: Sirnaomics Advances New siRNA Therapeutics Against HPV Infection And Cervical Cancer 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables
Number of Products under Development for Human Papillomavirus Infections, H2 2014 11
Number of Products under Development for Human Papillomavirus Infections - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Comparative Analysis by Unknown Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Investigation by Universities/Institutes, H2 2014 22
Human Papillomavirus Infections - Pipeline by Merck & Co., Inc., H2 2014 23
Human Papillomavirus Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 24
Human Papillomavirus Infections - Pipeline by MediGene AG, H2 2014 25
Human Papillomavirus Infections - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 26
Human Papillomavirus Infections - Pipeline by Crucell N.V., H2 2014 27
Human Papillomavirus Infections - Pipeline by Starpharma Holdings Limited, H2 2014 28
Human Papillomavirus Infections - Pipeline by Bharat Biotech International Limited, H2 2014 29
Human Papillomavirus Infections - Pipeline by FluGen, Inc., H2 2014 30
Human Papillomavirus Infections - Pipeline by Genticel, H2 2014 31
Human Papillomavirus Infections - Pipeline by Vaxart, Inc., H2 2014 32
Human Papillomavirus Infections - Pipeline by Selecta Biosciences, Inc., H2 2014 33
Human Papillomavirus Infections - Pipeline by Spider Biotech, H2 2014 34
Human Papillomavirus Infections - Pipeline by Indian Immunologicals Limited, H2 2014 35
Human Papillomavirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 36
Human Papillomavirus Infections - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H2 2014 37
Human Papillomavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2014 38
Human Papillomavirus Infections - Pipeline by Immunservice GmbH, H2 2014 39
Human Papillomavirus Infections - Pipeline by Redbiotec AG, H2 2014 40
Human Papillomavirus Infections - Pipeline by Agilvax, Inc., H2 2014 41
Human Papillomavirus Infections - Pipeline by Nielsen Biosciences, Inc., H2 2014 42
Assessment by Monotherapy Products, H2 2014 43
Number of Products by Stage and Target, H2 2014 45
Number of Products by Stage and Mechanism of Action, H2 2014 47
Number of Products by Stage and Route of Administration, H2 2014 49
Number of Products by Stage and Molecule Type, H2 2014 51
Human Papillomavirus Infections Therapeutics - Recent Pipeline Updates, H2 2014 90
Human Papillomavirus Infections - Dormant Projects, H2 2014 95
Human Papillomavirus Infections - Discontinued Products, H2 2014 96